Luulyo 16, joornaalka caalamiga ah ee heerka sare ah ee Nature Medicine ayaa daabacay xog cilmi baaris ah oo ku saabsan SHR-A1904, oo ah isku-darka daawada antibody-dawada (ADC) oo bartilmaameedsanaya claudin 18.2 (CLDN18.2), si loogu daaweeyo kansarka caloosha ee horumarsan ama kansarka isku-xirka caloosha iyo mindhicirka (GC/GEJC). Cilmi-baarayaashu waxay sameeyeen tijaabo caafimaad oo marxaladdii ugu horreysay ee aadanaha ah, oo saddex marxaladood ah, si loo qiimeeyo waxtarka SHR-A1904 95 bukaan oo hore loo daaweeyay oo qabay kansarka G/GEJ ee horumarsan ee CLDN18.2-positive.
Waqtigan xaadirka ah, waxaa weli jira tijaabooyin caafimaad oo badan oo ku saabsan teknoolojiyada cusub ee ka hortagga kansarka ee Shiinaha oo raadinaya bukaanno. La-tashi ku saabsan daawooyinka cusub iyo teknoolojiyada, waxaad la xiriiri kartaa Waaxda Caalamiga ah ee Isbitaalka Oncology ee Gobolka Koonfureed ee Beijing.
Lambarka Taleefanka: 4008803716
Aqoonsiga WeChat: 17801183037
Email：myimmnet@163.com
Claudin-18 isoform 2 (CLDN18.2), oo ah borotiin isku xiran oo laga helo epithelium-ka caloosha ee aan ahayn kan ugu daran isla markaana lagu soo bandhigo dusha sare ee unugyada burooyinka inta lagu jiro isbeddelka kansarka, waa bartilmaameed daaweyn oo rajo leh oo loogu talagalay kansarka isku xirka caloosha iyo mindhicirka (G/GEJ). SHR-A1904 waa isku-xidhka antibody-dawada oo ka kooban antibody monoclonal ah oo bartilmaameedsanaya CLDN18.2, oo ah DNA topoisomerase I inhibitor ah oo culays saaraya iyo isku-xidhe ku salaysan peptide oo la kala furi karo.
Marxaladda kor u kaca qiyaasta (0.6–8.0 mg kg−1), sunta xaddidaysa qiyaasta waxaa lagu arkay laba bukaan oo 4.8 mg kg−1 ah (fasalka 3aad ee qandhada iyo heerka 3aad ee bilirubin dhiigga oo kordhay) iyo hal bukaan oo 6.0 mg kg−1 ah (dhaawaca xuubka caloosha ee heerka 3aad). Qiyaasta ugu badan ee la adkaystay lama gaarin, 6.0 mg kg−1 iyo 8.0 mg kg−1 ayaa loo xushay fidinta daawada iyo waxtarka. Dhacdooyinka xun ee soo ifbaxaya ee daaweynta ayaa ka dhacay dhammaan 95 bukaan, oo inta badan ah dhiig-yaraan (72 (75.8%)), lallabbo (64 (67.4%)), hypoalbuminemia (61 (64.2%) iyo tirada unugyada dhiigga cad oo yaraatay (56 (58.9%)). Intaa waxaa dheer, 59 bukaan (62.1%) waxay la kulmeen dhacdooyin xun oo la xiriira daroogada heerka 3aad ama ka sarreeya. Lama soo sheegin dhimasho la xiriirta daaweynta. Bukaannada la qiimeyn karo jawaab celinta, heerka jawaab celinta ujeeddada la xaqiijiyay wuxuu ahaa 24.2% (95% muddada kalsoonida (CI), 11.1–42.3) 6.0 mg kg−1 iyo 25.0% (95% CI, 12.1–42.2) 8.0 mg kg−1. Badbaadada dhexdhexaadka ah ee aan horumarka lahayn waxay ahayd 5.6 bilood (95% CI, 3.0–6.9) 6.0 mg kg−1 iyo 5.8 bilood (95% CI, 3.0–8.6) 8.0 mg kg−1. Gunaanadkii, SHR-A1904 waxay muujisay muuqaal badbaado oo la maarayn karo waxayna dhiirigelisay dhaqdhaqaaqa ka hortagga burooyinka ee bukaanada qaba kansarka CLDN18.2-positive G/GEJ, taasoo u baahan baaritaan dheeraad ah.
Waqtigan xaadirka ah, waxaa weli jira tijaabooyin caafimaad oo badan oo ku saabsan teknoolojiyada cusub ee ka hortagga kansarka ee Shiinaha oo raadinaya bukaanno. La-tashi ku saabsan daawooyinka cusub iyo teknoolojiyada, waxaad la xiriiri kartaa Waaxda Caalamiga ah ee Isbitaalka Oncology ee Gobolka Koonfureed ee Beijing.
Lambarka Taleefanka: 4008803716
Aqoonsiga WeChat: 17801183037
Email：myimmnet@163.com
Waqtiga boostada: Luulyo-24-2025